Skip to content

Pennsylvania Medicaid

Does Pennsylvania Medicaid cover Zepbound?

No. Pennsylvania Medicaid's policies on file exclude Zepbound for weight loss on Medicaid plans.

Policy document

  • Medicaid: Not covered. Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of o...

Earliest policy review June 4, 2026. How we verify · Check your exact plan · Medicaid card names in Pennsylvania

Full requirements: Zepbound for Weight Loss (1 plan type)

Applies to Medicaid plans.

Not covered

Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of overweight or obesity for MA beneficiaries. The policy states: 'GLP-1 Receptor Agonists are not covered for the treatment of overweight or obesity.'

Policy note: Pennsylvania MA explicitly ended coverage of all GLP-1 receptor agonists for overweight/obesity effective January 1, 2026. Class-wide exclusion applies to Zepbound for weight loss indication.

Policy effective January 1, 2026 · verified June 4, 2026 · source: Mab2025112403 · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (1 plan type)

Applies to Medicaid plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial approval — Zepbound for moderate-to-severe OSA (non-preferred)

All of:

  • Recent BMI ≥ 35 kg/m2
  • Diagnosis of moderate to severe OSA confirmed within the last 2 years per most recent consensus treatment guidelines (e.g., AASM ICSD) OR baseline AHI ≥ 15 events/hour
  • At least one clinical OSA symptom: excessive daytime sleepiness (e.g., ESS ≥ 10) OR reduced sleep-related quality of life (snoring, nocturnal choking, insomnia, partner sleep disruption, morning headaches, nocturia, etc.)
  • Recent 6-month trial of lifestyle changes and behavioral modifications OR medical reason why immediate treatment is necessary
  • Age-appropriate per FDA labeling, compendia, or peer-reviewed literature
  • No contraindication to the prescribed drug
  • History of therapeutic failure of, OR contraindication to, OR intolerance to the maximum FDA-approved doses of Ozempic (semaglutide), Wegovy (semaglutide), AND Mounjaro (tirzepatide)

Plus any one of:

  • Utilization of PAP with documented adherence (≥ 4 hours/night on 70% of nights in a consecutive 30-day period)
  • PAP intolerance despite troubleshooting (mask issues, humidity, claustrophobia) AND: utilization of or intolerance to an oral appliance for OSA

Documentation to bring

  • Recent BMI documentation (≥ 35 kg/m2)
  • Documentation of moderate-to-severe OSA diagnosis within last 2 years: per AASM/consensus guidelines OR AHI ≥ 15 events/hour on sleep study
  • Documentation of at least one OSA clinical symptom: ESS score ≥ 10 (excessive daytime sleepiness) OR sleep-related quality of life impairment (snoring, nocturnal choking, insomnia, partner disruption, morning headaches, nocturia)
  • PAP adherence documentation: ≥ 4 hours/night on 70% of nights in a consecutive 30-day period — OR documentation of PAP intolerance with troubleshooting attempts AND utilization of or intolerance to an oral appliance
  • Documentation of 6-month prior trial of lifestyle changes and behavioral modifications OR medical reason for immediate treatment
  • Documentation of therapeutic failure of Ozempic (semaglutide) at max FDA-approved dose, AND Wegovy (semaglutide) at max FDA-approved dose, AND Mounjaro (tirzepatide) at max FDA-approved dose — OR contraindication/intolerance to each (with troubleshooting documentation over ≥ 1 month if intolerance-based)
  • Documentation of age-appropriateness per FDA labeling, compendia, or peer-reviewed literature
  • Documentation of no contraindication to Zepbound
  • If therapeutic duplication: documentation of intent to transition or medical reason for concomitant use

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: At least 5% weight loss from the starting weight.
  • Renewal: Renewal (OSA): (1) If on GLP-1 <6 months: documentation of lifestyle changes and behavioral modifications; (2) If on GLP-1 ≥6 months AND titration complete AND ≥3 consecutive months at max tolerated dose: must show 5% total body weight loss and documentation of dietary changes; (3) If on GLP-1 ≥6 months but titration not complete or <3 consecutive months at max tolerated dose: may approve up to 3-month trial extension at max tolerated dose with documentation of dietary changes; (4) PAP adherence or PAP intolerance with oral appliance trial maintained; (5) If on GLP-1 ≥1 year: must document improvement in OSA symptoms (e.g., decrease in AHI from baseline, improvement in daytime sleepiness); (6) Step-therapy: therapeutic failure/contraindication/intolerance to max doses of Ozempic, Wegovy, AND Mounjaro. BMI and AHI baseline not re-confirmed at renewal.

Not covered when

  • Mild OSA excluded (moderate-to-severe only, AHI ≥ 15)
  • Overweight/obesity treatment indication excluded
  • Saxenda (liraglutide) not covered for any indication

Policy note: Zepbound is non-preferred for OSA. Requires step-through therapeutic failure/contraindication/intolerance to maximum FDA-approved doses of ALL THREE of: Ozempic, Wegovy, AND Mounjaro before Zepbound. OSA diagnosis must be confirmed within last 2 years. PAP adherence is defined as ≥ 4 hours/night on 70% of nights in a consecutive 30-day period. PAP intolerance pathway requires documentation of troubleshooting strategies (mask issues, humidity, claustrophobia) and then either use of or intolerance to an oral appliance. Renewal at ≥6 months requires 5% total body weight loss (if titration complete and ≥3 months at max tolerated dose) with dietary change documentation; if not yet at max dose, up to 3-month extension may be approved. At ≥1 year, must document OSA symptom improvement (AHI reduction or daytime sleepiness improvement). Approval up to 6 months per cycle unless reviewer specifies otherwise. Prescriptions limited to 1-month supply per fill.

Policy effective January 1, 2026 · verified June 4, 2026 · source: Mab2025112403 · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

Pennsylvania Medicaid has separate Zepbound policies that don't depend on that benefit:

Questions people ask
Does Pennsylvania Medicaid cover Zepbound?
No. Pennsylvania Medicaid's policies on file exclude Zepbound for weight loss on Medicaid plans.
How long does a Zepbound approval last with Pennsylvania Medicaid?
Obstructive Sleep Apnea (OSA) — Applies to Medicaid plans. Initial approval: 6 months. Renewal: every 6 months.
What does Pennsylvania Medicaid require to renew Zepbound?
Obstructive Sleep Apnea (OSA) — Applies to Medicaid plans. At least 5% weight loss from the starting weight. Renewal (OSA): (1) If on GLP-1 <6 months: documentation of lifestyle changes and behavioral modifications; (2) If on GLP-1 ≥6 months AND titration complete AND ≥3 consecutive months at max tolerated dose: must show 5% total body weight loss and documentation of dietary changes; (3) If on GLP-1 ≥6 months but titration not complete or <3 consecutive months at max tolerated dose: may approve up to 3-month trial extension at max tolerated dose with documentation of dietary changes; (4) PAP adherence or PAP intolerance with oral appliance trial maintained; (5) If on GLP-1 ≥1 year: must document improvement in OSA symptoms (e.g., decrease in AHI from baseline, improvement in daytime sleepiness); (6) Step-therapy: therapeutic failure/contraindication/intolerance to max doses of Ozempic, Wegovy, AND Mounjaro. BMI and AHI baseline not re-confirmed at renewal.
How current is this information?
The oldest review date among the policies on this page is June 4, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Card and program names on file in Pennsylvania

These names map to Pennsylvania Medicaid, including older names and spelling variants. This is not a list of plans currently accepting members.

Also under Pennsylvania Medicaid: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Capital BlueCross, Highmark, Alabama Medicaid, California Medicaid, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid, Illinois Medicaid

All insurance plans · All medications

Summary of Pennsylvania Medicaid's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.